CR20170020A - Variantes de proteínas de unión al factor h y métodos de uso de estas - Google Patents

Variantes de proteínas de unión al factor h y métodos de uso de estas

Info

Publication number
CR20170020A
CR20170020A CR20170020A CR20170020A CR20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A CR 20170020 A CR20170020 A CR 20170020A
Authority
CR
Costa Rica
Prior art keywords
methods
factor
unions
variants
protein
Prior art date
Application number
CR20170020A
Other languages
English (en)
Spanish (es)
Inventor
Peter T Beernink
Original Assignee
Children´S Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children´S Hospital & Res Center At Oakland filed Critical Children´S Hospital & Res Center At Oakland
Publication of CR20170020A publication Critical patent/CR20170020A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20170020A 2014-07-23 2015-07-22 Variantes de proteínas de unión al factor h y métodos de uso de estas CR20170020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20170020A true CR20170020A (es) 2017-08-10

Family

ID=55163727

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170020A CR20170020A (es) 2014-07-23 2015-07-22 Variantes de proteínas de unión al factor h y métodos de uso de estas

Country Status (15)

Country Link
US (10) US10266572B2 (cg-RX-API-DMAC7.html)
EP (2) EP3172224B1 (cg-RX-API-DMAC7.html)
JP (4) JP6796057B2 (cg-RX-API-DMAC7.html)
KR (2) KR102752259B1 (cg-RX-API-DMAC7.html)
CN (3) CN106715464B (cg-RX-API-DMAC7.html)
AU (5) AU2015292615B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017001417B1 (cg-RX-API-DMAC7.html)
CA (2) CA3212723A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000558A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170020A (cg-RX-API-DMAC7.html)
ES (1) ES2922554T3 (cg-RX-API-DMAC7.html)
MX (3) MX382409B (cg-RX-API-DMAC7.html)
NZ (2) NZ729206A (cg-RX-API-DMAC7.html)
RU (1) RU2714248C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016014719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR101854309B1 (ko) 2016-11-16 2018-05-03 주식회사 케이엠더블유 Mimo 안테나 어셈블리
US11542467B2 (en) * 2017-12-04 2023-01-03 Intravacc B.V. Process for producing outer membrane vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組b型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
ATE503837T1 (de) 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
ATE492288T1 (de) * 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
MX2007008785A (es) 2005-01-27 2008-02-15 Childrens Hosp & Res Ct Oak Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
CN101160412A (zh) 2005-02-14 2008-04-09 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US9579372B2 (en) * 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
HRP20201076T1 (hr) 2009-03-24 2020-10-30 Glaxosmithkline Biologicals Sa Adjuvantni vezujući protein meningokokalnog faktora h
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
AU2010310985B2 (en) * 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
ES2661569T3 (es) * 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
CA2809758C (en) * 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
US9272006B2 (en) 2011-07-07 2016-03-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
MX351993B (es) * 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
JP2016527278A (ja) * 2013-08-02 2016-09-08 チルドレンズ ホスピタル アンド リサーチ センター オークランド 天然に生じないh因子結合タンパク質(fhbp)及びその使用の方法
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
AR102324A1 (es) * 2014-07-17 2017-02-22 Glaxosmithkline Biologicals Sa Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
CN106715464B (zh) 2021-03-16
US20250154206A1 (en) 2025-05-15
AU2019264600B2 (en) 2021-04-01
US11673920B2 (en) 2023-06-13
US10266572B2 (en) 2019-04-23
JP2025108722A (ja) 2025-07-23
US20200095288A1 (en) 2020-03-26
US10995122B2 (en) 2021-05-04
CA2955802A1 (en) 2016-01-28
EP4074726A3 (en) 2022-11-23
JP6796057B2 (ja) 2020-12-02
US20240025951A1 (en) 2024-01-25
US10487122B2 (en) 2019-11-26
KR102752259B1 (ko) 2025-01-13
US12129282B2 (en) 2024-10-29
MX2023000204A (es) 2023-02-09
CA2955802C (en) 2023-10-31
RU2020105192A (ru) 2020-02-12
NZ766003A (en) 2024-01-26
JP2021000121A (ja) 2021-01-07
AU2019264600A1 (en) 2019-12-05
US20210101942A1 (en) 2021-04-08
CO2017000558A2 (es) 2017-06-20
KR20230155595A (ko) 2023-11-10
US20250136648A1 (en) 2025-05-01
NZ766005A (en) 2024-03-22
CN106715464A (zh) 2017-05-24
EP3172224A4 (en) 2018-04-18
KR102761870B1 (ko) 2025-02-05
JP2017522877A (ja) 2017-08-17
WO2016014719A1 (en) 2016-01-28
US11834476B2 (en) 2023-12-05
MX382409B (es) 2025-03-13
CN112851768A (zh) 2021-05-28
BR112017001417A2 (pt) 2017-11-21
RU2017104742A (ru) 2018-08-29
US10836799B2 (en) 2020-11-17
AU2023204391A1 (en) 2023-08-03
BR112017001417B1 (pt) 2023-11-07
AU2023204391B2 (en) 2025-01-23
EP3172224B1 (en) 2022-06-29
US20190225655A1 (en) 2019-07-25
EP3172224A1 (en) 2017-05-31
MX2021005373A (es) 2021-07-06
US20200109179A1 (en) 2020-04-09
AU2015292615B2 (en) 2019-10-24
US20240101610A1 (en) 2024-03-28
RU2714248C2 (ru) 2020-02-13
EP4074726A2 (en) 2022-10-19
AU2015292615A1 (en) 2017-03-16
ES2922554T3 (es) 2022-09-16
CA3212723A1 (en) 2016-01-28
NZ766444A (en) 2024-01-26
US20210340191A1 (en) 2021-11-04
CN119613509A (zh) 2025-03-14
JP2023011916A (ja) 2023-01-24
US20170183384A1 (en) 2017-06-29
NZ729206A (en) 2022-07-01
AU2021203828A1 (en) 2021-07-08
JP7719046B2 (ja) 2025-08-05
US12269849B2 (en) 2025-04-08
RU2017104742A3 (cg-RX-API-DMAC7.html) 2019-02-27
KR20170028442A (ko) 2017-03-13
JP7221917B2 (ja) 2023-02-14
MX2017001038A (es) 2018-02-09
AU2025202774A1 (en) 2025-05-08
AU2021203828B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018005876A2 (es) Inmunoglobulinas conjugadas con lisina c-terminal
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112019012342A2 (pt) anticorpos il-11
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CA2971734C (en) Anti-pd-1 antibodies
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
BR112017023131A2 (pt) anticorpos anti- fcrn
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201791716A1 (ru) Фармацевтический состав
EA201691493A1 (ru) Замещенные n-арилпиридиноны
MX385740B (es) Matrices de proteínas naturales reestructuradas.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.